A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Lymphoma, Large B-Cell, Diffuse

abstract

  • ClinicalTrials.gov identifier NCT00435916.

publication date

  • June 12, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4065310

Digital Object Identifier (DOI)

  • 10.1186/1756-8722-7-44

PubMed ID

  • 24919462

Additional Document Info

start page

  • 44

volume

  • 7

number

  • 1